Katalog der Deutschen Nationalbibliothek

Go to:

Catalogue (Beta)

Knowledge Web

Person
Person

Person

Andreas Burchert (1969-)

Arzt

Name

Andreas Burchert

Time

1969- (Date of birth and death)

Place

Deutschland

Academic degree

Prof. Dr. med.

Profession

Arzt (characteristic profession)

Further information

Diss. Fachbereich Humanmedizin (1997, Humboldt-Univ. Berlin); Leitender Oberarzt an der Klinik für Hämatologie, Onkologie und Immunologie, Universitätsklinikum Marburg

Record type

Person

GND-Identifier

120512874

Record ID

120512874

Involved in

show all

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

A German-wide systematic study on mobilization and collection of hematopoietic stem cells in poor mobilizer patients with multiple myeloma prior to autologous stem cell transplantation

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study

Mobilization and hematopoietic stem cell collection in poor mobilizing patients with lymphoma: final results of the german OPTIMOB study

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Potenzial des Ultraschalls bei allogener Stammzelltransplantation und transplantationsassoziierten Komplikationen

Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Rolle von ICSBP in der Genetik BCR-ABL-induzierter Transformation und bei der Resistenzentstehung von BCR-ABL-transformierten Zellen gegenüber Imatinib

Untersuchung von Mechanismen der Transformation durch die Axl-Rezeptortyrosinkinase mit Hilfe retroviral erzeugter Axl-Virus-Mutanten
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal